If You Invested in Inspira Tech (IINNW)

Inspira Technologies Oxy B.H.N. Ltd. (Nasdaq: IINN, IINNW) is a medical technology company in the life support and respiratory treatment arena. The company focuses on respiratory support and extracorporeal life support technologies that are intended to offer alternatives to traditional invasive mechanical ventilation for patients with acute respiratory failure and critical cardiopulmonary conditions.

According to the company’s public statements, Inspira is developing its proprietary Augmented Respiration Technology, branded as INSPIRA ART. This device is described as a groundbreaking system that targets the large global mechanical ventilation market and is intended to elevate and stabilize decreasing oxygen saturation levels in minutes without the use of a ventilator, while patients remain awake during treatment. The INSPIRA ART platform is being designed to work with a clip-on HYLA blood sensor, a real-time continuous blood monitoring technology that aims to alert physicians to changes in a patient’s condition without the need for intermittent blood samples.

Inspira’s first commercial system in this platform is the INSPIRA ART100, a cardiopulmonary bypass system used in extracorporeal circulation of blood. Company disclosures state that the INSPIRA ART100 has obtained U.S. Food and Drug Administration 510(k) clearance for use in cardiopulmonary bypass (CBP) procedures and Israeli AMAR certification for both extracorporeal membrane oxygenation (ECMO) and cardiopulmonary bypass procedures. The system utilizes a technique that adds oxygen to the blood and removes carbon dioxide, returning enriched blood to the patient and taking over the functionality of the heart and/or lungs in critical care settings.

The INSPIRA ART100 incorporates proprietary software designed to guide medical teams through step-by-step setup and to support procedures in complex care environments. Company materials describe features such as system-activated alarm troubleshooting, a prominent screen with advanced software for accessible data display, and the ability to integrate with a hospital’s established procedures and safety practices. The system is described as having a small footprint, providing several hours of uptime in emergency scenarios, and being compatible with various types of disposable equipment available on the market.

Beyond the ART100, Inspira reports that it is designing and developing additional technologies within the same respiratory and life support ecosystem. These include the next-generation INSPIRA ART device, also referred to as the INSPIRA ART500 or Gen 2; the INSPIRA Cardi-ART portable modular device; the VORTX Oxygen Delivery System (also described as a blood oxygenation delivery technology); and the HYLA blood sensor itself. The company states that these products are in design and development stages, have not yet been tested or used in humans, and have not been approved by any regulatory entity.

Inspira highlights the potential clinical role of its technologies in intensive care units, emergency rooms, operating rooms, and other hospital units where patients may require extracorporeal circulation and advanced respiratory support. The company’s communications emphasize the goal of supporting medical professionals in treating patients with acute respiratory failure and other severe cardiopulmonary conditions by providing systems that can manage oxygenation and carbon dioxide removal and offer continuous blood monitoring.

In addition to its technology development, Inspira’s public announcements reference collaborations and distribution activities. These include delivery of INSPIRA ART100 systems to a U.S. distributor for deployment to hospitals on the U.S. east coast, preparation for deployment at a leading U.S. hospital, and showcasing the ART100 at a major healthcare exhibition in the Middle East. The company has also announced a collaboration with a specialized medical device manufacturer to establish a dedicated production line for a flow mechanism used in extracorporeal circulation of blood during the oxygenation process.

Company disclosures also describe the expansion of the HYLA blood sensor concept into an immediate personalized blood lab testing approach. The HYLA business model, as described by Inspira, is designed to reduce or replace the need for intermittent physical blood samples during extracorporeal procedures by providing real-time blood work with pre-determined setup options, or by supporting rapid intermittent blood work testing and analysis near the patient’s bed. The company states that this approach is intended to reduce reliance on central laboratories, remove the need for blood cartridges, and lessen the burden on hospital staff.

Inspira’s SEC filings show that it files as a foreign private issuer on Form 20-F and furnishes current reports on Form 6-K under the Securities Exchange Act of 1934. These filings often incorporate press releases related to product development milestones, regulatory progress, purchase orders, government-related discussions, and capital markets activities, such as private placements and sales agreements for its ordinary shares.

Overall, Inspira Technologies Oxy B.H.N. Ltd. presents itself as a specialty medical device and technology company focused on extracorporeal life support, cardiopulmonary bypass systems, and continuous blood monitoring solutions, with the stated aim of improving respiratory and life support treatment in critical care environments.